NCT03161613View on ClinicalTrials.gov

Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

July 17, 2017

Primary Completion Date

April 1, 2019

Study Completion Date

April 1, 2019

Conditions
Multiple Indications Cancer
Interventions
OTHER

Non-Interventional

Non-Interventional

Trial Locations (1)

14050

Local Institution, Mexico City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03161613 - Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico | Biotech Hunter | Biotech Hunter